These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
890 related articles for article (PubMed ID: 9762378)
21. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. Reusch JE; Gadsby R Diabetes Technol Ther; 2003; 5(4):685-93. PubMed ID: 14511423 [TBL] [Abstract][Full Text] [Related]
22. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Palumbo PJ Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500 [TBL] [Abstract][Full Text] [Related]
23. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644 [TBL] [Abstract][Full Text] [Related]
24. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes. Viberti G J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064 [TBL] [Abstract][Full Text] [Related]
26. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
27. Optimal glycemic control in type 2 diabetic patients. Does including insulin treatment mean a better outcome? Vaaler S Diabetes Care; 2000 Apr; 23 Suppl 2():B30-4. PubMed ID: 10860188 [TBL] [Abstract][Full Text] [Related]
28. Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes. Teleb M; Popp Switzer M; Elhanafi S; Elfar A; San Juan ZT Curr Cardiol Rep; 2016 Mar; 18(3):29. PubMed ID: 26886228 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Yki-Järvinen H Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990 [TBL] [Abstract][Full Text] [Related]
30. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Boyne MS; Saudek CD Diabetes Care; 1999 Apr; 22 Suppl 3():C45-53. PubMed ID: 10189562 [TBL] [Abstract][Full Text] [Related]
31. Managing type 2 diabetes: going beyond glycemic control. Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582 [TBL] [Abstract][Full Text] [Related]
32. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Hall GC; McMahon AD; Carroll D; Home PD Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442 [TBL] [Abstract][Full Text] [Related]
33. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Vasudevan AR; Burns A; Fonseca VA Treat Endocrinol; 2006; 5(5):273-86. PubMed ID: 17002487 [TBL] [Abstract][Full Text] [Related]
34. Glycemic control and complications in type 2 diabetes mellitus. Stolar M Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730 [TBL] [Abstract][Full Text] [Related]
35. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Konig M; Lamos EM; Stein SA; Davis SN Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412 [TBL] [Abstract][Full Text] [Related]